Money Concepts Capital Corp Sells 6,248 Shares of Gilead Sciences, Inc. $GILD

Money Concepts Capital Corp cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 79,857 shares of the biopharmaceutical company’s stock after selling 6,248 shares during the quarter. Money Concepts Capital Corp’s holdings in Gilead Sciences were worth $11,130,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in GILD. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC increased its position in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares in the last quarter. Quattro Advisors LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC raised its stake in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth approximately $28,000. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. Daiwa Securities Group decreased their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Rothschild & Co Redburn dropped their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Truist Financial reduced their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday. Leerink Partners decreased their price objective on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Finally, Morgan Stanley lowered their target price on Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a research note on Wednesday. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $159.04.

Gilead Sciences Price Performance

GILD opened at $134.84 on Friday. The company has a fifty day moving average price of $129.76 and a two-hundred day moving average price of $134.99. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a 52 week low of $107.75 and a 52 week high of $157.29. The firm has a market capitalization of $167.41 billion, a PE ratio of 18.37 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 83,000 shares of company stock valued at $10,824,500. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.